Angiotensin II receptor blockers in the prevention of atrial fibrillation. - Wikidata - awgldk - TriplyDB

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

http://www.wikidata.org/entity/Q37494662

about

New developments in atrial antiarrhythmic drug therapy.Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model.

P2860

Q37697498-C8C82F7A-1726-477A-BF14-2DC0D25ED38D Q53820825-5B774622-0AD8-4AF6-900E-02A279FFC996

P2860

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

http://www.wikidata.org/entity/Q37494662

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@en

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@nl

type

label

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@en

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@nl

prefLabel

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@en

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@nl

P1433

Q37494662-16314A5C-4E58-493B-B814-0040C9EBBAA3

P1476

Q37494662-425ADF22-117E-49AA-876A-71348EF0C69E

P2093

Q37494662-37F5B93C-7AD0-4AD4-9240-1D264125CA33

Q37494662-55F26D7A-DE30-4CA9-97F0-C9B42724170A

Q37494662-9697FC36-DBDC-4C58-8C83-6C3B15D00A47

Q37494662-E0088C43-EE41-4CCE-9610-DAAF6E68D292

Q37494662-F2F57102-3575-4CD6-9CA1-6DDCB9B19AD4

P2860

Q37494662-0170FB26-EBEA-49FF-BC3C-AF84BF6A6123

Q37494662-02E863A3-C657-409F-95B0-83C295A5C348

Q37494662-094B7947-8E04-427E-8587-626329FCC0AC

Q37494662-0B83173B-5277-4CA7-B180-4046435F4818

Q37494662-0C4331A3-54E1-4AFD-9F08-9439685EE906

Q37494662-1692A963-51C3-4D82-8D1D-1F6FCB4AF1E6

Q37494662-190DB4BA-AE36-4911-BE0A-41DD2A6375E0

Q37494662-219B310A-1140-4AF4-BEA6-5284EEF45F1A

Q37494662-224BB08D-ED06-4F87-9189-AB60C0D8B540

Q37494662-2548F121-1FB4-44F2-A7CD-36AF07865146

P304

Q37494662-6CCCE933-1D08-4F98-86AB-04D83593CFEA

P31

Q37494662-CB0EA021-8F5B-4159-BF7D-5A667F3342FD

P356

Q37494662-49E92A7B-8353-4DA9-8A0C-0C6D816D08F0

P407

Q37494662-1BA3607F-7B66-4F21-A587-5631A35FEF87

P433

Q37494662-F2DF1015-07CC-4198-818D-326DDC03610A

P478

Q37494662-46ED00EF-1E5B-4915-8F64-843E34D79A36

P577

Q37494662-070EE6AC-33C9-46A3-9A8E-32137F6A81F7

P698

Q37494662-C03DF194-3A9B-4A7B-B162-611DEA6D1A80

P921

Q37494662-7565F239-DB1A-409F-96C7-C74E6261D64A

P356

14656560902973736

P1433

Expert Opinion on Pharmacotherapy

P1476

Angiotensin II receptor blockers in the prevention of atrial fibrillation.

@en

P2093

Alfredo Madrid

http://www.w3.org/2001/XMLSchema#string

Giancarlo Vitagliano

http://www.w3.org/2001/XMLSchema#string

Giovanni Gaeta

http://www.w3.org/2001/XMLSchema#string

Nunzia Silvestri

http://www.w3.org/2001/XMLSchema#string

Silvia Barra

http://www.w3.org/2001/XMLSchema#string

P2860

KCNQ1 gain-of-function mutation in familial atrial fibrillation

Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation.

Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB

Effect of dronedarone on cardiovascular events in atrial fibrillation

Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation.

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

P304

1395-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656560902973736

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19466911

http://www.w3.org/2001/XMLSchema#string

P921

atrial fibrillation